Is prolactin (PRL) associated with Zollinger-Ellison Syndrome (ZES)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prolactin and Zollinger-Ellison Syndrome: No Direct Association

Prolactin is not associated with Zollinger-Ellison Syndrome (ZES). These are distinct endocrine conditions with separate pathophysiologic mechanisms and no established clinical relationship.

Understanding the Distinct Entities

Zollinger-Ellison Syndrome Pathophysiology

  • ZES is caused by gastrin-secreting neuroendocrine tumors (gastrinomas) that result in gastric acid hypersecretion, leading to severe peptic ulcer disease and diarrhea 1, 2.
  • The syndrome occurs either sporadically (62-80% of cases) or as part of Multiple Endocrine Neoplasia Type 1 (MEN-1) syndrome (20-38% of cases) 3, 4.
  • Gastrin directly and indirectly stimulates parietal cells to secrete acid and induces hyperplasia of parietal and enterochromaffin-like cells 1.

Hyperprolactinemia Pathophysiology

  • Prolactin elevation results from prolactinomas, medications, hypothyroidism, renal/hepatic disease, or pituitary stalk compression 5.
  • Hyperprolactinemia inhibits gonadotropin secretion via suppression of hypothalamic kisspeptin, leading to hypogonadism 5.
  • Clinical manifestations include galactorrhea, menstrual disturbances, infertility, and sexual dysfunction—none of which are features of ZES 6.

The MEN-1 Connection: An Important Caveat

While prolactin and ZES are not directly related, there is an indirect association through MEN-1 syndrome:

  • MEN-1 patients can develop both prolactinomas AND gastrinomas as part of their multi-glandular endocrine tumor syndrome 6, 1.
  • In MEN-1, these represent separate tumor manifestations of the same genetic syndrome, not a causal relationship between prolactin and gastrin 4.
  • Patients with ZES and a family history of MEN-1 or associated endocrinopathies should be evaluated for other MEN-1 manifestations, which could include prolactinoma 1.

Clinical Implications

When to Measure Prolactin in ZES Patients

  • Prolactin measurement is NOT routinely indicated in ZES unless there are specific symptoms of hyperprolactinemia 6.
  • Consider prolactin testing only if the patient presents with: delayed puberty, galactorrhea, menstrual disturbances, visual field defects, or if MEN-1 syndrome is suspected 6.

When to Consider ZES in Hyperprolactinemia Patients

  • ZES evaluation is NOT indicated in patients with hyperprolactinemia unless they have gastrointestinal symptoms suggestive of gastrinoma 1, 2.
  • Suspect ZES only if there is severe erosive esophagitis, multiple or refractory peptic ulcers, peptic ulcers with diarrhea, or family history of MEN-1 1.

Diagnostic Approach for Each Condition

For Suspected Hyperprolactinemia

  • Measure serum prolactin in a single blood sample at any time of day 7.
  • Use age-specific and sex-specific reference ranges 5, 7.
  • Exclude hypothyroidism, renal/hepatic impairment, and medication causes 5, 7.

For Suspected ZES

  • Measure fasting serum gastrin level (>100 pg/mL suggests ZES; >1000 pg/mL with gastric pH <2 is diagnostic) 2.
  • Perform secretin stimulation test for mild hypergastrinemia 1, 2.
  • Localize tumors with somatostatin receptor scintigraphy and endoscopic ultrasound 1.

The key clinical takeaway: Do not conflate these separate conditions unless evaluating for MEN-1 syndrome, where both may coexist as independent manifestations.

References

Research

Zollinger-Ellison Syndrome.

Current treatment options in gastroenterology, 2003

Research

Management of patients with Zollinger-Ellison syndrome.

Annual review of medicine, 1995

Guideline

Etiology of Hyperprolactinemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Guidelines for Lab and Imaging Monitoring in Hyperprolactinemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.